# Study to Assess The Efficacy and Safety of a PARP Inhibitor For The Treatment of BRCA-positive Advanced Breast Cancer

> **NCT00494234** · PHASE2 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 54 (actual)

## Conditions studied

- Breast Neoplasms

## Interventions

- **DRUG:** Olaparib

## Key facts

- **NCT ID:** NCT00494234
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-06-15
- **Primary completion:** 2009-02-27
- **Final completion:** 2022-12-21
- **Target enrollment:** 54 (ACTUAL)
- **Last updated:** 2024-01-19

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00494234

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00494234, "Study to Assess The Efficacy and Safety of a PARP Inhibitor For The Treatment of BRCA-positive Advanced Breast Cancer". Retrieved via AI Analytics 2026-08-17 from https://api.ai-analytics.org/clinical/NCT00494234. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*